Oculis Shares Are Trading Higher After the Company Announced It Expanded Its DIAMOND Program With Global Retina Experts and Is Accelerating Its Phase 3 Trials for DME Treatment.
Oculis Shares Are Trading Higher After the Company Announced It Expanded Its DIAMOND Program With Global Retina Experts and Is Accelerating Its Phase 3 Trials for DME Treatment.
Oculis股票交易走高，因該公司宣佈擴大其金剛石項目，與全球視網膜專家合作，並加快進行DME治療的3期試驗。
Oculis Shares Are Trading Higher After the Company Announced It Expanded Its DIAMOND Program With Global Retina Experts and Is Accelerating Its Phase 3 Trials for DME Treatment.
Oculis股價上漲，因爲該公司宣佈擴大其金剛石項目，與全球視網膜專家合作，並加快進行DME治療的第3階段試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間